Systematic Evaluation of the Metabolism and Toxicity of Thiazolidinone and Imidazolidinone Heterocycles

Chemical Research in Toxicology

Volumn 28, Issue 10, 2015, Pages 2019-2033

  Tang, Shi Qing ^a   Lee, Yong Yang Irvin ^a   Packiaraj, David Sheela ^a   Ho, Han Kiat ^a   Chai, Christina Li Lin ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2,4 DIOXOTHIAZOLIDIN 3 YL) ACETIC ACID; 2 (2,5 DIOXOIMIDAZOLIDIN 1 YL) ACETIC ACID; 2 (4 BENZYLIDENE 2,5 DIOXOIMIDAZOLIDIN 1 YL) ACETIC ACID; 2 (4 BENZYLIDENE 5 OXO 2 THIOXOIMIDAZOLIDIN 1 YL) ACETIC ACID; 2 (4 OXO 2 THIOXOTHIAZOLIDIN 3 YL) ACETIC ACID; 2 (5 BENZYLIDENE 2,4 DIOXOTHIAZOLIDIN 3 YL) ACETIC ACID; 2 (5 OXO 2 THIOXOIMIDAZOLIDIN 1 YL) ACETIC ACID; 2,4 THIAZOLIDINEDIONE DERIVATIVE; CYTOCHROME P450 2E1; ETHYL 2 (5 OXO 2 THIOXOIMIDAZOLIDIN 1 YL) ACETATE; GLUTATHIONE; HETEROCYCLIC KETONE; HYDANTOIN DERIVATIVE; IMIDAZOLE DERIVATIVE; METHYL 2 (2,5 DIOXOIMIDAZOLIDIN 1 YL) ACETATE; RHODANINE; THIAZOLE DERIVATIVE; THIOHYDANTOIN DERIVATIVE; TRANSFORMING GROWTH FACTOR ALPHA; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT; CYTOCHROME P450; IMIDAZOLIDINE DERIVATIVE;

ANIMAL CELL; ARTICLE; BIOLOGICAL ACTIVITY; CELL VIABILITY; DRUG METABOLISM; DRUG SCREENING; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HYDROPHILICITY; LIVER CELL; LIVER MICROSOME; LIVER TOXICITY; METABOLIC STABILITY; NONHUMAN; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; HALF LIFE TIME; HEPG2 CELL LINE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; METABOLISM; PRECLINICAL STUDY; STRUCTURE ACTIVITY RELATION; TANDEM MASS SPECTROMETRY; TUMOR CELL LINE;

CELL LINE, TUMOR; CELL SURVIVAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; DRUG EVALUATION, PRECLINICAL; GLUTATHIONE; HALF-LIFE; HEP G2 CELLS; HUMANS; HYPOGLYCEMIC AGENTS; IMIDAZOLIDINES; MICROSOMES, LIVER; STRUCTURE-ACTIVITY RELATIONSHIP; TANDEM MASS SPECTROMETRY; THIAZOLIDINEDIONES;

EID: 84944790441     PISSN: 0893228X     EISSN: 15205010     Source Type: Journal    
DOI: 10.1021/acs.chemrestox.5b00247     Document Type: Article

References (39)

1. Meusel, M. and Gütschow, M. (2004) Recent Developments in Hydantoin Chemistry. A Review Org. Prep. Proced. Int. 36, 391-443 10.1080/00304940409356627
2. Tomasic, T. and Masic, L. P. (2009) Rhodanine as a Privileged Scaffold in Drug Discovery Curr. Med. Chem. 16, 1596-1629 10.2174/092986709788186200
3. Vengurlekar, S., Sharma, R., and Trivedi, P. (2012) A Study on the Biological Activity of 2-Thioxo-imidazolidin-4-ones Lett. Drug Design Discovery 9, 549-555 10.2174/157018012800389322
4. Jain, V. S., Vora, D. K., and Ramaa, C. S. (2013) Thiazolidine-2,4-diones: Progress Towards Multifarious Applications Bioorg. Med. Chem. 21, 1599-1620 10.1016/j.bmc.2013.01.029
5. Food and Drug Administration (2015) http://www.accessdata.fda.gov/scripts/cder/drugsatfda/ (accessed Jun 2015).
6. Ono Pharmaceutical Co., Ltd. (2005) Kinedak (Epalrestat) Packageinsert, Chuo-ku, Osaka, Japan.
7. Baell, J. B. and Holloway, G. A. (2010) New Substructure Filters for Removal of Pan Assay Interference Compounds (PAINS) from Screening Libraries and for Their Exclusion in Bioassays J. Med. Chem. 53, 2719-2740 10.1021/jm901137j
8. DeSimone, R. W., Currie, K. S., Mitchell, S. A., Darrow, J. W., and Pippin, D. A. (2004) Privileged Structures: Applications in Drug Discovery Comb. Chem. High Throughput Screening 7, 473-493 10.2174/1386207043328544
9. Evans, B. E., Rittle, K. E., Bock, M. G., DiPardo, R. M., Freidinger, R. M., Whitter, W. L., Lundell, G. F., Veber, D. F., and Anderson, P. S. (1988) Methods for Drug Discovery: Development of Potent, Selective, Orally Effective Cholecystokinin Antagonists J. Med. Chem. 31, 2235-2246 10.1021/jm00120a002
10. Mendgen, T., Steuer, C., and Klein, C. D. (2012) Privileged Scaffolds or Promiscuous Binders: A Comparative Study on Rhodanines and Related Heterocycles in Medicinal Chemistry J. Med. Chem. 55, 743-753 10.1021/jm201243p
11. Welsch, M. E., Snyder, S. A., and Stockwell, B. R. (2010) Privileged Scaffolds for Library Design and Drug Discovery Curr. Opin. Chem. Biol. 14, 347-361 10.1016/j.cbpa.2010.02.018
12. Baell, J. and Walters, M. A. (2014) Chemistry: Chemical Con Artists Foil Drug Discovery Nature 513, 481 10.1038/513481a
13. Sink, R., Gobec, S., Pecar, S., and Zega, A. (2010) False Positives in the Early Stages of Drug Discovery Curr. Med. Chem. 17, 4231-4255 10.2174/092986710793348545
14. Tomašić, T. and Peterlin Mašič, L. (2012) Rhodanine as a Scaffold in Drug Discovery: A Critical Review of its Biological Activities and Mechanisms of Target Modulation Expert Opin. Drug Discovery 7, 549-560 10.1517/17460441.2012.688743
15. Alvarez-Sánchez, R., Montavon, F., Hartung, T., and Pähler, A. (2006) Thiazolidinedione Bioactivation: A Comparison of the Bioactivation Potentials of Troglitazone, Rosiglitazone, and Pioglitazone using Stable Isotope-labeled Analogues and Liquid Chromatography Tandem Mass Spectrometry Chem. Res. Toxicol. 19, 1106-1116 10.1021/tx050353h
16. Astellas Pharma US (2012) I. XTANDI® (Enzalutamide) Capsules, http://www.astellas.us/docs/us/12A005-ENZ-WPI.pdf (accessed Jun 2015).
17. Cox, P. J., Ryan, D. A., Hollis, F. J., Harris, A.-M., Miller, A. K., Vousden, M., and Cowley, H. (2000) Absorption, Disposition, and Metabolism of Rosiglitazone, a Potent Thiazolidinedione Insulin Sensitizer, in Humans Drug Metab. Dispos. 28, 772-780
18. Cuttle, L., Munns, A. J., Hogg, N. A., Scott, J. R., Hooper, W. D., Dickinson, R. G., and Gillam, E. M. J. (2000) Phenytoin Metabolism by Human Cytochrome P450: Involvement of P450 3A and 2C Forms in Secondary Metabolism and Drug-Protein Adduct Formation Drug Metab. Dispos. 28, 945-950
19. Isley, W. L. (2003) Hepatotoxicity of Thiazolidinediones Expert Opin. Drug Saf. 2, 581-586 10.1517/14740338.2.6.581
20. Jaakkola, T., Laitila, J., Neuvonen, P. J., and Backman, J. T. (2006) Pioglitazone is Metabolised by CYP2C8 and CYP3A4 in vitro: Potential for Interactions with CYP2C8 Inhibitors Basic Clin. Pharmacol. Toxicol. 99, 44-51 10.1111/j.1742-7843.2006.pto-437.x
21. Kassahun, K., Pearson, P. G., Tang, W., McIntosh, I., Leung, K., Elmore, C., Dean, D., Wang, R., Doss, G., and Baillie, T. A. (2001) Studies on the Metabolism of Troglitazone to Reactive Intermediates in Vitro and in Vivo. Evidence for Novel Biotransformation Pathways Involving Quinone Methide Formation and Thiazolidinedione Ring Scission Chem. Res. Toxicol. 14, 62-70 10.1021/tx000180q
22. Krause, T., Gerbershagen, M., Fiege, M., Weisshorn, R., and Wappler, F. (2004) Dantrolene-A Review of its Pharmacology, Therapeutic Use and New Developments Anaesthesia 59, 364-373 10.1111/j.1365-2044.2004.03658.x
23. Jonen, H. (1980) Reductive and Oxidative Metabolism of Nitrofurantoin in Rat Liver Naunyn-Schmiedeberg's Arch. Pharmacol. 315, 167-175 10.1007/BF00499260
24. Ramirez, M. A. and Borja, N. L. (2008) Epalrestat: An Aldose Reductase Inhibitor for the Treatment of Diabetic Neuropathy Pharmacotherapy. 28, 646-655 10.1592/phco.28.5.646
25. Fan, Y.-H., Chen, H., Natarajan, A., Guo, Y., Harbinski, F., Iyasere, J., Christ, W., Aktas, H., and Halperin, J. A. (2004) Structure-activity Requirements for the Antiproliferative Effect of Troglitazone Derivatives Mediated by Depletion of Intracellular Calcium Bioorg. Med. Chem. Lett. 14, 2547-2550 10.1016/j.bmcl.2004.02.087
26. Knasmüller, S., Mersch-Sundermann, V., Kevekordes, S., Darroudi, F., Huber, W., Hoelzl, C., Bichler, J., and Majer, B. (2004) Use of Human-derived Liver Cell Lines for the Detection of Environmental and Dietary Genotoxicants; Current State of Knowledge Toxicology 198, 315-328 10.1016/j.tox.2004.02.008
27. Roe, A., Snawder, J., Benson, R., Roberts, D., and Casciano, D. (1993) HepG2 cells: An in vitro Model for P450-dependent Metabolism of Acetaminophen Biochem. Biophys. Res. Commun. 190, 15-19 10.1006/bbrc.1993.1003
28. Lançon, A., Hanet, N., Jannin, B., Delmas, D., Heydel, J.-M., Lizard, G., Chagnon, M.-C., Artur, Y., and Latruffe, N. (2007) Resveratrol in Human Hepatoma HepG2 Cells: Metabolism and Inducibility of Detoxifying Enzymes Drug Metab. Dispos. 35, 699-703 10.1124/dmd.106.013664
29. Bernardo, P. H., Sivaraman, T., Wan, K.-F., Xu, J., Krishnamoorthy, J., Song, C. M., Tian, L., Chin, J. S., Lim, D. S., and Mok, H. Y. (2011) Synthesis of a Rhodanine-based Compound Library Targeting Bcl-XL and Mcl-1 Pure Appl. Chem. 83, 723-731 10.1351/PAC-CON-10-10-29
30. Sing, W. T., Lee, C. L., Yeo, S. L., Lim, S. P., and Sim, M. M. (2001) Arylalkylidene Rhodanine with Bulky and Hydrophobic Functional Group as Selective HCV NS3 Protease Inhibitor Bioorg. Med. Chem. Lett. 11, 91-94 10.1016/S0960-894X(00)00610-7
31. Wu, J. C., Merlino, G., Cveklova, K., Mosinger, B., and Fausto, N. (1994) Autonomous Growth in Serum-free Medium and Production of Hepatocellular Carcinomas by Differentiated Hepatocyte Lines that Overexpress Transforming Growth Factor α Cancer Res. 54, 5964-5973
32. Gan, J., Harper, T. W., Hsueh, M.-M., Qu, Q., and Humphreys, W. G. (2005) Dansyl Glutathione as a Trapping Agent for the Quantitative Estimation and Identification of Reactive Metabolites Chem. Res. Toxicol. 18, 896-903 10.1021/tx0496791
33. Kajiya, K., Ichiba, M., Kuwabara, M., Kumazawa, S., and Nakayama, T. (2001) Role of Lipophilicity and Hydrogen Peroxide Formation in the Cytotoxicity of Flavonols Biosci., Biotechnol., Biochem. 65, 1227-1229 10.1271/bbb.65.1227
34. Nava-Ocampo, A. A. and Bello-Ramírez, A. M. (2004) Lipophilicity Affects the Pharmacokinetics and Toxicity of Local Anaesthetic Agents Administered by Caudal Block Clin. Exp. Pharmacol. Physiol. 31, 116-118 10.1111/j.1440-1681.2004.03961.x
35. GraphPad Prism 5.0, GraphPad Software Inc., La Jolla, CA, www.graphpad.com.
36. Pang, Y. Y., Yeo, W. K., Loh, K. Y., Go, M. L., and Ho, H. K. (2014) Structure-toxicity Relationship and Structure-activity Relationship Study of 2-Phenylaminophenylacetic Acid Derived Compounds Food Chem. Toxicol. 71, 207-216 10.1016/j.fct.2014.06.013
37. Arsovska, E., Trontelj, J., Zidar, N., Tomašić, T., Mašič, L. P., Kikelj, D., Plavec, J., and Zega, A. (2014) Evaluation of Michael-type Acceptor Reactivity of 5-Benzylidenebarbiturates, 5-Benzylidenerhodanines, and Related Heterocycles Using NMR Acta Chim. Slov. 61, 637-644
38. Yu, L., Jiang, Y., Wang, L., Sheng, R., Hu, Y., and Zeng, S. (2013) Metabolism of BYZX in Human Liver Microsomes and Cytosol: Identification of the Metabolites and Metabolic Pathways of BYZX PLoS One 8, e59882 10.1371/journal.pone.0059882
39. Chen, H., Soroka, D., Zhu, Y., and Sang, S. (2013) Metabolism of Ginger Component [6]-Shogaol in Liver Microsomes from Mouse, Rat, Dog, Monkey, and Human Mol. Nutr. Food Res. 57, 865-876 10.1002/mnfr.201200708